Financial Performance - The company's operating revenue for 2022 was ¥200,345,457.02, representing a 27.92% increase compared to ¥156,618,305.30 in 2021[21]. - The net profit attributable to shareholders was -¥12,694,776.12, an improvement of 33.63% from -¥19,125,950.55 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,050,428.56, a 21.53% improvement from -¥29,373,370.76 in 2021[21]. - Cash generated from operating activities increased by 55.35% to ¥166,381,243.04, up from ¥107,098,005.73 in 2021[21]. - The total assets at the end of 2022 were ¥553,064,727.36, a decrease of 16.11% from ¥659,245,600.20 at the end of 2021[26]. - The net assets attributable to shareholders decreased by 17.24% to ¥13,771,203.62 from ¥16,640,394.08 in 2021[26]. - The company reported a weighted average return on equity of -123.33% for 2022, compared to -112.47% in 2021[26]. - The company received government subsidies amounting to ¥6,829,849.35 in 2022, down from ¥8,630,913.98 in 2021[28]. - The total non-operating income and expenses for 2022 amounted to ¥10,355,652.44, slightly higher than ¥10,247,420.21 in 2021[29]. Business Strategy and Focus - The company has undergone a strategic adjustment in its major business focus from real estate and publishing to biomedicine and cell technology services since 2015[20]. - The company is actively involved in research and development in new products and technologies within the biomedicine sector[20]. - The company is positioned in a growing stem cell industry, with increasing government support for research and application in this field[33]. - The company aims to enhance the quality, reliability, and traceability of its products and services through information management and standard operating procedures[43]. - The company is focused on integrating existing R&D resources to create a tiered development framework in the biopharmaceutical field[103]. Revenue Breakdown - The company's total revenue for the reporting period was 200.35 million yuan, with the biopharmaceutical segment generating 142.70 million yuan, an increase of 18.15% year-on-year, and the energy-saving and environmental protection segment generating 57.48 million yuan, an increase of 60.35% year-on-year[42]. - The revenue from the energy-saving technology service sector was ¥57,480,136.60, accounting for 28.69% of total revenue, with a significant growth of 60.35% from ¥35,845,757.38 in 2021[58]. - The biopharmaceutical sector generated ¥142,696,749.00, which is 71.23% of total revenue, reflecting an 18.15% increase from ¥120,772,547.92 in the previous year[58]. - The revenue from cell storage and testing services was ¥135,930,334.24, which accounted for 67.85% of the total revenue from the biopharmaceutical sector[58]. Research and Development - The company has submitted nearly 30 intellectual property applications in the past three years, demonstrating its commitment to research and technology innovation in the field of stem cell storage and clinical applications[43]. - R&D investment increased by 16.88% to ¥9,985,226.68 in 2022, accounting for 4.98% of operating revenue[73]. - The company is in the project initiation phase for a new hydrogel scaffold material for mesenchymal stem cell transplantation, aiming to provide experimental data for clinical research[71]. - The company has completed the extraction and quality control process for mesenchymal stem cell exosomes, which may fill a gap in the field of stem cell exosome quality control[72]. Governance and Management - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operations, and no fund occupation by the controlling shareholder[116]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[117]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[120]. - The company has committed to compliance and governance, with independent directors and a dedicated audit team ensuring transparency and accountability[138][140]. Market Expansion and Future Plans - In 2023, the company aims to optimize its asset-liability structure and enhance its financial resilience by issuing shares to specific investors, which is currently in progress[102]. - The company plans to strengthen its R&D capabilities by collaborating with research institutions and universities, focusing on stem cell and immune cell technologies[103]. - Market expansion plans include entering two new provinces, targeting an additional 500,000 users[147]. - The company has completed a strategic acquisition of a local biotech firm for 100 million yuan to enhance its product portfolio[147]. Employee and Talent Management - The total number of employees at the end of the reporting period was 512, with 287 in sales and 58 in production[164]. - The educational background of employees includes 7 with a doctorate, 33 with a master's degree, and 160 with a bachelor's degree[165]. - The company has implemented a training program that includes internal, external, and online training methods[166]. - The company emphasizes the importance of talent development and plans to build a robust talent cultivation system to support its strategic goals[105]. Legal and Compliance - The company faced a lawsuit regarding a technical authorization agreement, with a claimed amount of CNY 737.99 million, but it has not formed a provision for this liability[197]. - The company has not faced any penalties or rectifications during the reporting period[200]. - The company has not engaged in any illegal occupation of assets or funds during the reporting period[189]. Financial Management - The company reported a significant increase in cash flow from its cell storage business, contributing positively to cash flow despite overall net losses[80]. - The company has committed to avoiding any form of competition with its controlling shareholders and related enterprises[186]. - The company guarantees that all related transactions will be conducted at market prices and in compliance with relevant regulations[187].

南华生物医药股份有限公司2021年年度报告全文 南华生物医药股份有限公司 2021 年年度报告 ...

Key Financial Data [Key Accounting Data and Financial Indicators](index=2&type=section&id=%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved significant revenue growth and turned profitable in the first three quarters of 2022, with net profit attributable to parent company shareholders up 106.44%, despite a decline in total assets Key Accounting Data and Financial Indicators | Indicator | Year-to-Date as of Report Period End | YTD vs. Prior Period Change | | :--- | :--- | :--- | | Operating Revenue (CNY) | 156,404,576.30 | 52.40% | | Net Profit Attributable to Shareholders of the Listed Company (CNY) | 540,721.32 | 106.44% | | Net Profit Attributable to Shareholders of the Listed Company After Deducting Non-recurring Gains and Losses (CNY) | -6,212,530.03 | 46.46% | | Net Cash Flow from Operating Activities (CNY) | 130,252,235.42 | 364.07% | | Basic Earnings Per Share (CNY/share) | 0.0017 | 106.30% | | **Indicator** | **As of End of Current Period** | **Vs. Prior Year-End Change** | | Total Assets (CNY) | 596,009,995.11 | -9.59% | | Total Equity Attributable to Shareholders of the Listed Company (CNY) | 17,181,115.40 | 3.25% | [Non-recurring Gains and Losses and Their Amounts](index=2&type=section&id=%28II%29%20Non-recurring%20Gains%20and%20Losses%20and%20Their%20Amounts) Year-to-date, non-recurring gains and losses totaled **6.75 million CNY**, primarily from government grants, which was key to achieving positive net profit Non-recurring Gains and Losses | Item | YTD Amount (CNY) | Description | | :--- | :--- | :--- | | Government grants recognized in current profit or loss | 3,565,005.85 | - | | Other non-operating income and expenses apart from the above | 4,619,397.82 | - | | Impact on minority interests (after tax) | -1,282,115.66 | - | | **Total** | **6,753,251.35** | **--** | [Changes and Reasons for Key Financial Indicators](index=3&type=section&id=%28III%29%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Significant financial changes include increased financial assets held for trading, decreased prepayments, increased short-term borrowings, and reduced other payables; revenue grew over 50%, with credit impairment losses reversing Key Financial Indicator Changes and Reasons | Statement Item | Change Percentage | Reason for Change | | :--- | :--- | :--- | | **Balance Sheet** | | | | Financial assets held for trading | 2014.90% | Primarily due to debt-to-equity conversion by a subsidiary and current period purchases of wealth management products | | Prepayments | -70.90% | Due to recovery of business prepayments from canceled procurement agreements in the current period | | Short-term borrowings | 91.33% | Increase in bank borrowings | | Other payables | -35.93% | Primarily due to repayment of 100 million CNY loan from Caixin Financial Holdings in the current period | | **Income Statement** | | | | Operating revenue | 52.40% | Continued growth in the company's cell business and new heating business revenue compared to the prior period | | Operating cost | 282.60% | Increase in operating revenue led to a corresponding increase in costs | | Other income | 394.03% | Increase in government grants received in the current period | | Credit impairment losses | 150.01% | Recovery of accounts receivable from energy-saving and medical device trading businesses in the current period, leading to a reversal of corresponding bad debts | Shareholder Information [Common Shareholder Shareholding](index=4&type=section&id=%28I%29%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Shareholding) As of the report period end, the company had **13,960** common shareholders; the controlling shareholder holds **25.58%**, with some top shareholders having pledged shares - As of the report period end, the total number of common shareholders was **13,960**[13](index=13&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held | Pledge Status | | :--- | :--- | :--- | :--- | :--- | | Hunan Caixin Industrial Fund Management Co., Ltd. | State-owned Legal Person | 25.58% | 79,701,655 | None | | Shanghai Heping Bulk Equity Investment Fund Management Co., Ltd. | Domestic Non-state-owned Legal Person | 11.43% | 35,600,000 | Pledged 35,600,000 | | Hefei Xijing Technology Co., Ltd. | Domestic Non-state-owned Legal Person | 4.66% | 14,522,162 | None | - The company's controlling shareholder, Caixin Industrial Fund, has no related party or concerted action relationship with other shareholders; relationships among other circulating shareholders are unknown[14](index=14&type=chunk) Other Significant Matters [Other Significant Matters](index=6&type=section&id=III.%20Other%20Significant%20Matters) No other significant matters required disclosure during the reporting period - The company had no other significant matters requiring disclosure in this reporting period[16](index=16&type=chunk) Quarterly Financial Statements (Unaudited) [Consolidated Balance Sheet](index=6&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of September 30, 2022, total assets were **596.01 million CNY**, down 9.59%; total liabilities were **477.53 million CNY**, down 13.01% due to debt repayment; equity attributable to parent company shareholders was **17.18 million CNY**, a slight increase Consolidated Balance Sheet Data | Item | September 30, 2022 (CNY) | January 1, 2022 (CNY) | | :--- | :--- | :--- | | Total Assets | 596,009,995.11 | 659,245,600.20 | | Total Liabilities | 477,530,805.14 | 548,926,321.40 | | Total Equity Attributable to Parent Company Shareholders | 17,181,115.40 | 16,640,394.08 | | Total Equity | 118,479,189.97 | 110,319,278.80 | [Consolidated Income Statement](index=8&type=section&id=2.%20Consolidated%20Income%20Statement%20from%20Year-Beginning%20to%20Report%20Period%20End) In the first three quarters of 2022, operating revenue reached **156.40 million CNY**, up 52.40%, with total operating costs at **152.42 million CNY**, up 40.70%; net profit was **8.16 million CNY**, a turnaround from a **5.36 million CNY** net loss, with parent company net profit at **0.54 million CNY** Consolidated Income Statement Data | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | I. Total Operating Revenue | 156,404,576.30 | 102,630,862.82 | | II. Total Operating Costs | 152,421,445.83 | 108,336,750.17 | | III. Operating Profit | 8,389,117.25 | -6,144,236.87 | | IV. Total Profit | 13,007,165.63 | -3,236,487.92 | | V. Net Profit | 8,159,911.17 | -5,357,485.10 | | 1. Net Profit Attributable to Parent Company Shareholders | 540,721.32 | -8,401,491.52 | | 2. Minority Interests | 7,619,189.85 | 3,044,006.42 | [Consolidated Cash Flow Statement](index=10&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement%20from%20Year-Beginning%20to%20Report%20Period%20End) In the first three quarters of 2022, operating cash flow was a strong net inflow of **130.25 million CNY**, up 364.07%; investing cash flow was a net outflow of **20.89 million CNY**, while financing cash flow was a net outflow of **73.54 million CNY** due to debt repayment; cash and cash equivalents at period end totaled **188.83 million CNY** Consolidated Cash Flow Statement Data | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 130,252,235.42 | 28,067,646.06 | | Net Cash Flow from Investing Activities | -20,892,052.90 | -20,418,020.02 | | Net Cash Flow from Financing Activities | -73,539,523.05 | 24,749,939.87 | | Net Increase in Cash and Cash Equivalents | 35,820,788.38 | 32,399,541.03 | | Cash and Cash Equivalents at Period End | 188,825,485.09 | 99,437,580.79 | [Audit Status](index=11&type=section&id=%28II%29%20Audit%20Report) The company's 2022 third-quarter report is unaudited - The company's third-quarter report is unaudited[24](index=24&type=chunk)

Financial Performance - The company's operating revenue for the first half of 2022 was ¥109,777,202.11, representing a 62.87% increase compared to ¥67,401,236.63 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥2,166,923.99, a significant turnaround from a loss of ¥6,298,477.35 in the previous year, marking a 134.40% improvement[19]. - The net cash flow from operating activities reached ¥111,323,801.11, a remarkable increase of 1,533.93% compared to a negative cash flow of ¥7,763,557.85 in the same period last year[19]. - Basic and diluted earnings per share improved to ¥0.0070, up 134.65% from a loss of ¥0.0202 per share in the previous year[19]. - The weighted average return on net assets was 12.23%, a recovery of 39.12% from -26.89% in the same period last year[19]. - The operating cost increased significantly by 338.53% to ¥49,672,972.00, up from ¥11,327,132.48, primarily due to the increase in operating revenue[53]. - The company reported a significant increase in other income, which rose by 290.13% to ¥2,277,057.77, mainly due to government subsidies received[53]. - The total profit for the first half of 2022 was CNY 6,384,666.19, a significant improvement from a total loss of CNY 3,880,301.46 in the previous year[164]. Assets and Liabilities - Total assets decreased by 14.71% to ¥562,260,133.11 from ¥659,245,600.20 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 13.02% to ¥18,807,318.07 from ¥16,640,394.08 at the end of the previous year[19]. - The company's cash and cash equivalents decreased by 54.81% to ¥7,046,281.82 from ¥15,593,355.93, primarily due to cash outflows from investment and financing activities[53]. - Accounts receivable amounted to ¥194,983,489, accounting for 34.68% of total assets, an increase of 4.93% from the previous year[63]. - Total liabilities decreased to CNY 448,064,145.00 from CNY 548,926,321.40, indicating a reduction of approximately 18.4%[157]. - Current liabilities totaled CNY 430,191,289.89, down from CNY 529,002,426.65, a decrease of about 18.7%[157]. Market and Industry Trends - The global stem cell industry is entering a rapid growth phase, with China's market share increasing from 18.8% in 2016 to 21.9% in 2020[30]. - The cell therapy market in China is expected to grow from 1.3 billion yuan in 2021 to 10.2 billion yuan by 2023, with a compound annual growth rate of 181.5%[31]. - The environmental protection industry in China is projected to maintain a growth rate of 15-20% during the 14th Five-Year Plan period[32]. - The company operates in two main sectors: "biomedicine" and "energy conservation and environmental protection"[28]. Research and Development - The company is actively involved in stem cell storage and application research, supported by various national policies[29]. - The number of new stem cell drug application projects in the first half of 2022 reached 8, indicating a growing interest in the field[31]. - The company is focused on upstream cell storage technology services while simultaneously conducting technology research and development[36]. - The company is actively engaged in the research and development of new medical technologies and products, which is crucial for future growth[77]. Strategic Initiatives - The company plans to expand its market presence in energy-saving products and services, particularly in urban heating operations, which is expected to drive future revenue growth[60]. - The company plans to enhance brand awareness and improve employee expertise to increase the conversion rate of newborn stem cell storage[85]. - The company intends to increase investment in technology research and development, leveraging national and local support policies for the stem cell industry to create new growth points[85]. - The company plans to enhance governance, internal control systems, and talent development to address bottlenecks in rapid growth[92]. Risks and Challenges - The company faces risks related to changes in tax incentives for energy-saving projects, which could adversely affect profitability if it no longer qualifies for such benefits[86]. - The company is exposed to funding recovery risks due to the long project cycles in the energy-saving sector, which may strain liquidity and increase operational risks[87]. - The company reported a significant decline in potential customer base due to a decreasing birth rate, with national birth rates recorded at 10.41‰, 8.52‰, and 7.52‰ from 2019 to 2021, respectively[81]. Shareholder Information - The company plans to issue up to 18,449,197 A-shares to its controlling shareholder, raising no more than RMB 276 million to supplement working capital[134]. - The total number of ordinary shareholders at the end of the reporting period is 14,059[141]. - Hunan Caixin Industrial Fund holds 25.58% of the shares, totaling 79,701,650 shares[141]. - The company has not reported any share buyback progress[139]. Compliance and Governance - The half-year financial report has not been audited[110]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[108].

Financial Performance - The company's operating revenue for 2021 was ¥156,618,305.30, a decrease of 10.79% compared to ¥175,564,990.41 in 2020[19] - The net profit attributable to shareholders of the listed company was -¥19,125,950.55 in 2021, representing a decline of 334.54% from a profit of ¥8,154,550.92 in 2020[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -29,373,370.76 CNY, a decrease of 619.46% compared to the previous year[20] - The operating cash flow was 107,098,005.73 CNY, an increase of 151.68% compared to the previous year[20] - The total assets at the end of 2021 were 659,245,600.20 CNY, representing an 18.54% increase from the end of 2020[20] - The net assets attributable to shareholders decreased by 37.37% to 16,640,394.08 CNY compared to the end of 2020[20] - The revenue from main business after deductions was 137,487,362.78 CNY, compared to 175,432,248.87 CNY in 2020[21] - The company reported a quarterly operating revenue of 53,987,442.48 CNY in Q4 2021, showing a positive trend in the latter part of the year[25] - The company received government subsidies amounting to 8,630,913.98 CNY, which are closely related to its normal business operations[26] Business Strategy and Focus - The company has shifted its main business focus to biomedicine and cell technology services since 2015, moving away from its previous real estate and publishing operations[18] - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[6] - The company is positioned in a rapidly growing industry, with significant government support for biomedicine and cell therapy technologies[31] - The company is committed to enhancing its competitive advantage in the biopharmaceutical industry through innovation and collaboration in research and development[37] - The company plans to focus on core technologies and deepen its main business, particularly in stem cell and immune cell technology applications[97] - The company aims to enhance resource allocation and adjust its operational and marketing strategies in 2022[97] Research and Development - The company has completed over 50 national-level research projects, including the "973 Program" and "863 Program," resulting in 200+ high-level SCI research papers and 17 national invention patents[42] - The company is actively involved in research projects, including the use of umbilical cord mesenchymal stem cells for treating pediatric biliary atresia and neural stem cell therapy for Alzheimer's disease[37] - The company initiated multiple R&D projects, including a new culture system for umbilical cord mesenchymal stem cells, with expected completion by December 2022[66] - R&D investment increased by 71.68% from 4,976,335.90 yuan in 2020 to 8,543,248.85 yuan in 2021, with R&D investment as a percentage of operating revenue rising from 2.83% to 5.45%[71] Market Position and Growth - The cell therapy market in China is expected to grow from 1.3 billion CNY in 2021 to 10.2 billion CNY by 2023, with a compound annual growth rate of 181.5%[32] - The company achieved a total revenue of CNY 156.62 million in 2021, with the biopharmaceutical segment generating CNY 120.77 million, representing a year-on-year growth of 23.48%[38] - The environmental protection segment reported revenue of CNY 35.85 million, showing a significant decline of 53.90% compared to the previous year[38] - The company reported a total revenue of 259.97 million in 2021, with a net loss of 12.18 million[93] Governance and Management - The actual controller of the company is the Hunan Provincial Government, with the largest shareholder being the Hunan Caixin Industrial Fund Management Co., Ltd., a state-owned enterprise[39] - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors through various channels[114] - The company has held 1 annual general meeting and 3 extraordinary general meetings during the reporting period, ensuring compliance with legal requirements for shareholder meetings[109] - The board of directors has undergone changes, with new appointments aimed at strengthening governance and strategic direction[127] - The company has appointed independent directors with extensive experience in finance and law, strengthening its oversight capabilities[135][136] Financial Management and Expenses - Sales expenses increased by 53.35% to ¥57,682,332.01 due to higher revenue from cell business and the establishment of new subsidiaries[65] - Management expenses rose by 57.95% to ¥48,234,324.81, driven by increased personnel and relocation costs[65] - Financial expenses surged by 324.81% to ¥13,988,841.62, primarily due to the continued use of a significant loan from a major shareholder[65] - The total remuneration for directors, supervisors, and senior management in the reporting period amounted to CNY 3.0992 million[146] Employee and Talent Development - The total number of employees at the end of the reporting period was 539, with 11 in the parent company and 528 in major subsidiaries[159] - The professional composition included 309 sales personnel, 55 production personnel, 31 technical personnel, 23 financial personnel, and 121 administrative personnel[160] - The company has a training plan that includes internal training, external training, and online training to enhance employee skills[161] - The company emphasizes the importance of talent development, planning to stabilize the current R&D team while attracting top technical personnel to enhance research capabilities[102] Compliance and Risk Management - The internal control system has been effectively established and executed, with no significant deficiencies reported[165] - The company maintained effective internal control over financial reporting as of December 31, 2021[171] - The audit committee held 2 meetings during the reporting period, discussing the annual report and financial statements[156] - The company did not identify any risks during the supervisory activities of the supervisory board in the reporting period[158] Environmental and Social Responsibility - The company faced an administrative penalty due to a wastewater detection equipment failure, resulting in a fine of 20,000 yuan[176] - There were no significant environmental issues reported during the period, and the company is not classified as a key pollutant discharge unit[176] - The company has not reported any activities related to poverty alleviation or rural revitalization[179]

南华生物医药股份有限公司 2022 年第一季度报告全文 证券代码：000504 证券简称：南华生物 公告编号：2022-044 南华生物医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 64,818,635.90 | 33,131,542.07 | 95.64% | | 归属于上市公司股东的净利润（元） | 159,904.25 | ...

南华生物医药股份有限公司 2021 年第三季度报告 证券代码：000504 证券简称：南华生物 公告编号：2021-050 南华生物医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 1 南华生物医药股份有限公司 2021 年第三季度报告 | 归属于上市公司股东的 | 18,167,038.87 | 26,568,530.39 | -31.62% | | --- | --- | --- | --- | | 所有者权益（元） | | | | (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位 ...

证券代码：000504 证券简称：南华生物 公告编号：2021-036 南华生物医药股份有限公司 关于参加 2021 年度湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流工作，构建和谐投资者关系，南华生物医 药股份有限公司（以下简称"公司"）将参加由湖南证监局、湖南省上市公司协 会、深圳市全景网络有限公司共同举办的"2021年度湖南辖区上市公司投资者网 上集体接待日活动"，现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的平台举行，投资者 可以登录"全景·路演天下"（http://rs.p5w.net/），参与本次投资者集体接 待日活动。上市公司与投资者网上互动的时间为2021年9月24日（星期五）下午 15:00至16:55。届时公司将通过网络在线交流形式与投资者就公司治理、发展战 略、经营状况、融资计划和可持续发展等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 南华生物医药股份有限公司董事会 2021 年 9 月 23 日 1 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥67,401,236.63, representing a 60.34% increase compared to ¥42,037,618.31 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was -¥6,298,477.35, a decrease of 201.34% from -¥2,090,149.71 in the previous year[21]. - The net cash flow from operating activities was -¥7,763,557.85, which is a 573.10% decline compared to -¥1,153,404.04 in the same period last year[21]. - Total assets at the end of the reporting period were ¥595,863,641.93, an increase of 7.14% from ¥556,140,141.52 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 23.71%, from ¥26,568,530.39 to ¥20,270,053.04[21]. - The basic earnings per share were -¥0.0202, a decline of 188.57% from -¥0.007 in the previous year[21]. - The diluted earnings per share were also -¥0.0202, reflecting the same percentage decline as the basic earnings per share[21]. - The weighted average return on net assets was -26.89%, a decrease of 14.86% from -12.03% in the previous year[21]. Revenue Segmentation - The company achieved a total revenue of 67.40 million yuan, with the biopharmaceutical segment generating 58.69 million yuan, representing a year-on-year growth of 68.48%[29]. - The energy-saving and environmental protection segment reported revenue of 8.71 million yuan, reflecting a year-on-year increase of 20.95%[29]. - The company reported a significant increase in revenue from the biopharmaceutical sector, which accounted for 87.08% of total revenue, up from 82.87% in the previous year[46]. Research and Development - The company has established a clinical application research system for cell technology, supported by a team of renowned experts and scholars, including Nobel laureate Gregg L. Semenza[32]. - The company has formed strategic partnerships with various domestic and international research institutions and universities to enhance its research and development capabilities[32]. - The company holds 17 national invention patents and 4 international invention patents, showcasing its strong R&D capabilities[34]. - The company is involved in multiple research projects, including the use of umbilical cord mesenchymal stem cells for treating various conditions, currently in different stages of development[35]. - The company has published over 200 high-level SCI research papers, indicating its commitment to scientific research and innovation[34]. - The company has received two first-class awards for scientific and technological progress from Hunan Province, reflecting its achievements in research[34]. Operational Challenges - The company reported a non-operating loss of 231.68 million yuan, with a tax impact of 45.95 million yuan[26]. - The company recorded a fair value loss of 52.93 million yuan from trading financial assets and derivatives[25]. - The company’s subsidiaries, such as Nanhua Peace Hospital Management, reported a net loss of ¥3,072,199.00, indicating challenges in the healthcare management sector[60]. - The company faced an administrative penalty of 200,000 yuan due to wastewater discharge exceeding standards, which will impact its operating expenses[84]. Market and Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[6]. - The report highlights potential risks and countermeasures in the company's operations, urging investors to be aware of investment risks[5]. - The company is actively expanding its market presence in Hunan Province, with ongoing collaborations in basic and clinical research[36]. - The company aims to diversify its product pipeline by expanding into adult immune cell and adipose-derived mesenchymal stem cell storage projects to mitigate the impact of declining birth rates[67]. - The company intends to extend its industrial chain and increase investment in technology and hardware to explore new growth points in the stem cell industry[68]. Financial Position and Liabilities - The company's total liabilities increased to CNY 466,878,573.92 as of June 30, 2021, compared to CNY 421,658,651.59 at the end of 2020, marking an increase of about 10.7%[143]. - The total equity decreased to CNY 128,985,068.01 as of June 30, 2021, down from CNY 134,481,489.93 at the end of 2020, reflecting a decline of about 4.1%[143]. - The company reported a beginning balance of 2,685.89 million yuan in receivables from related parties, with a new addition of 56.1 million yuan and repayments of 148.78 million yuan, resulting in an ending balance of 2,593.21 million yuan[102]. - The company incurred financial expenses of 605.38 million yuan and management expenses of 27.50 million yuan due to related party debts, leading to a reduction in net profit by 632.88 million yuan[102]. Governance and Compliance - The company did not distribute cash dividends or bonus shares for the half-year period, nor did it increase capital through reserves[80]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[79]. - The company has not engaged in any related party transactions during the reporting period[98]. - The company's semi-annual financial report has not been audited[92]. Future Outlook and Risks - The company acknowledges the risk of talent loss, which is critical for its sustainable development in the technology-intensive energy-saving service sector[72]. - The company plans to enhance its energy-saving and environmental protection services to achieve a win-win situation while increasing the cash recovery rate of related businesses[73]. - The company faces risks related to changes in tax policies that could affect its profitability in the energy-saving and environmental protection sector[69]. - The birth rate in China has been declining, with rates of 10.89‰ in 2018, 10.41‰ in 2019, and 8.52‰ in 2020, which poses a risk to the company's potential customer base[64].

Financial Performance - The company's operating revenue for Q1 2021 was ¥33,131,542.07, representing a 79.02% increase compared to ¥18,507,279.73 in the same period last year[8] - Net profit attributable to shareholders was ¥957,093.09, a significant turnaround from a loss of ¥1,600,061.19, marking a 159.82% improvement[8] - The net cash flow from operating activities reached ¥4,984,040.45, up 387.73% from a negative cash flow of ¥1,732,165.50 in the previous year[8] - Basic earnings per share improved to ¥0.0031 from a loss of ¥0.005, reflecting a 162.00% increase[8] - The weighted average return on equity was 3.54%, a recovery from -9.18% in the same period last year, showing a 12.72% improvement[8] - The total operating profit for the first quarter was 2,268,519.66, compared to a loss of 843,409.34 in the previous period[52] - The net profit for the first quarter reached 1,695,629.28, while the previous period recorded a net loss of 562,222.11[52] - The total comprehensive income for the first quarter was 1,695,629.28, compared to a loss of 562,222.11 in the previous period[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥553,921,445.80, a slight decrease of 0.40% from ¥556,140,141.52 at the end of the previous year[8] - The total liabilities as of March 31, 2021, were CNY 417,778,303.89, slightly down from CNY 421,658,651.59 at the end of 2020, a decrease of 0.9%[45] - The total assets amounted to CNY 553,921,445.80 as of March 31, 2021, compared to CNY 556,140,141.52 at the end of 2020, indicating a decrease of 0.4%[45] - The total non-current liabilities remained stable at CNY 3,184,118.81 as of March 31, 2021, compared to CNY 3,397,408.80 at the end of 2020, a decrease of 6.3%[45] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,307[12] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., held 25.58% of the shares, amounting to 79,701,655 shares[12] - The company's equity attributable to shareholders was CNY 27,525,623.48, up from CNY 26,568,530.39 in the previous quarter, an increase of 3.6%[45] Cash Flow - Cash received from sales of goods and services amounted to ¥58,205,844.11, a 189.09% increase, indicating strong performance in cell storage and energy-saving businesses[16] - The company received cash related to operating activities of ¥22,486,725.77, a significant increase of 1854.41% due to returned cooperation funds[17] - The total cash inflow from operating activities was 80,694,093.59, significantly higher than 21,284,855.98 in the previous period[59] - The net cash flow from financing activities was 11,641,006.58 CNY, a recovery from a negative cash flow of -30,272,358.34 CNY in the previous period[61] - The total cash and cash equivalents at the end of the period increased to 78,865,117.52 CNY, compared to 16,532,938.25 CNY in the previous period[61] Expenses and Investments - Short-term loans increased by 130.82% to ¥30,041,861.12 due to new bank borrowings[16] - Research and development expenses rose by 47.44% to ¥1,516,040.88, reflecting increased investment in R&D[16] - The company reported a financial expense of CNY 1,940,114.12 in Q1 2021, significantly higher than CNY 705,214.26 in the same period last year, an increase of 174.5%[51] - The company reported a loss of 66,908,000 CNY from securities investments during the reporting period[29] - The company’s financial expenses rose by 175.11% to ¥1,940,114.12, attributed to increased interest expenses from higher borrowings[16] Corporate Governance - Nanhua Biopharmaceutical Co., Ltd. reported a commitment to maintain independent operations and financial integrity, ensuring no illegal occupation of assets or funds[21] - The company guarantees that its financial personnel operate independently from controlling shareholders and other enterprises[22] - Nanhua Biopharmaceutical has not controlled any companies with similar business operations as of the date of the commitment letter, ensuring no competition exists[23] - The company commits to avoiding related transactions with controlled enterprises and will ensure fair market pricing for any unavoidable transactions[25] - Nanhua Biopharmaceutical will not utilize its shareholder status to harm the interests of other shareholders[26] - The company has made commitments regarding asset restructuring and will notify relevant parties of any potential conflicts of interest[28] - The company has established a complete governance structure and independent management system to ensure operational independence[22] - Nanhua Biopharmaceutical will independently handle its financial decisions and tax obligations[22] - The company has pledged to cease any competitive business operations if future expansions overlap with its existing business[24] - Nanhua Biopharmaceutical's commitments are valid as long as it remains a publicly traded company and its controlling shareholders maintain their status[23]